JP2025503707A5 - - Google Patents

Info

Publication number
JP2025503707A5
JP2025503707A5 JP2024542044A JP2024542044A JP2025503707A5 JP 2025503707 A5 JP2025503707 A5 JP 2025503707A5 JP 2024542044 A JP2024542044 A JP 2024542044A JP 2024542044 A JP2024542044 A JP 2024542044A JP 2025503707 A5 JP2025503707 A5 JP 2025503707A5
Authority
JP
Japan
Prior art keywords
antigen
antibody
binding fragment
seq
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024542044A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025503707A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2023/051100 external-priority patent/WO2023139107A1/en
Publication of JP2025503707A publication Critical patent/JP2025503707A/ja
Publication of JP2025503707A5 publication Critical patent/JP2025503707A5/ja
Pending legal-status Critical Current

Links

JP2024542044A 2022-01-18 2023-01-18 ガレクチン－１０抗体 Pending JP2025503707A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2200597.9 2022-01-18
GB202200597 2022-01-18
PCT/EP2023/051100 WO2023139107A1 (en) 2022-01-18 2023-01-18 Galectin-10 antibodies

Publications (2)

Publication Number Publication Date
JP2025503707A JP2025503707A (ja) 2025-02-04
JP2025503707A5 true JP2025503707A5 (enExample) 2026-03-03

Family

ID=85037098

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024542044A Pending JP2025503707A (ja) 2022-01-18 2023-01-18 ガレクチン－１０抗体

Country Status (10)

Country Link
US (1) US20250059285A1 (enExample)
EP (1) EP4466070A1 (enExample)
JP (1) JP2025503707A (enExample)
KR (1) KR20240133711A (enExample)
CN (1) CN118488967A (enExample)
AU (1) AU2023208882A1 (enExample)
CA (1) CA3236108A1 (enExample)
IL (1) IL314367A (enExample)
MX (1) MX2024006275A (enExample)
WO (1) WO2023139107A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118206657B (zh) * 2023-12-29 2025-03-07 康旭生物科技(深圳)有限公司 一种半乳糖凝集素-3的抗体及其应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
CA2118508A1 (en) 1992-04-24 1993-11-11 Elizabeth S. Ward Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
JPH08511420A (ja) 1993-06-16 1996-12-03 セルテック・セラピューテイクス・リミテッド 抗 体
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
KR100940380B1 (ko) 1999-01-15 2010-02-02 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
JP4336498B2 (ja) 2000-12-12 2009-09-30 メディミューン，エルエルシー 延長した半減期を有する分子ならびにその組成物および用途
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
WO2004029207A2 (en) 2002-09-27 2004-04-08 Xencor Inc. Optimized fc variants and methods for their generation
EP2368578A1 (en) 2003-01-09 2011-09-28 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
US8163881B2 (en) 2005-05-31 2012-04-24 The Board Of Regents Of The University Of Texas System Immunoglobulin molecules with improved characteristics
EP2275443B1 (en) 2008-04-11 2015-12-02 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
GB2461546B (en) 2008-07-02 2010-07-07 Argen X Bv Antigen binding polypeptides
CA2934644C (en) 2013-12-24 2023-11-21 Argen-X N.V. Fcrn antagonists and methods of use
GB201707484D0 (en) 2017-05-10 2017-06-21 Argenx Bvba Method of preparing ph-dependent antibodies
AU2019250689A1 (en) 2018-04-13 2020-10-08 Universiteit Gent Galectin-10 antibodies

Similar Documents

Publication Publication Date Title
JP2025111463A5 (enExample)
JP2021520825A5 (enExample)
JP2021526022A5 (enExample)
RU2018112243A (ru) Молекулы, связывающиеся с тимусным стромальным лимфопоэтином (tslp), и способы применения таких молекул
CN111615519B (zh) 结合人il-5的单克隆抗体、其制备方法和用途
JP2023093753A5 (enExample)
JP2020537520A5 (enExample)
JP2022122865A5 (enExample)
CN110869390A (zh) 抗pd-l1抗体及其用途
JP2025501775A5 (enExample)
JP2015503909A5 (enExample)
JP2025183307A5 (enExample)
JP2020522280A5 (enExample)
JP2024540148A5 (enExample)
JP2025514437A5 (enExample)
JP2023545183A5 (enExample)
JP2023545182A5 (enExample)
RU2017104638A (ru) Нейтрализующие антитела к вирусу гриппа B и пути их применения
CN106565840A (zh) 抗乙肝表面抗原的抗体及其用途
JP2022548646A5 (enExample)
TWI853912B (zh) 包含抗il-5抗體的醫藥組成物及其用途
JP2016520595A5 (enExample)
WO2024131949A1 (zh) Anti-cMet抗体、抗体药物偶联物及其制备方法和用途
CN115315442B (zh) Sars-cov-2抗体及其应用
JPWO2022044573A5 (enExample)